tradingkey.logo

MaxCyte Inc

MXCT
1.630USD
+0.130+8.67%
收盤 12/22, 16:00美東報價延遲15分鐘
173.83M總市值
虧損本益比TTM

MaxCyte Inc

1.630
+0.130+8.67%

關於 MaxCyte Inc 公司

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.

MaxCyte Inc簡介

公司代碼MXCT
公司名稱MaxCyte Inc
上市日期Mar 29, 2016
CEOMasoud (Maher)
員工數量114
證券類型Ordinary Share
年結日Mar 29
公司地址9713 Key West Avenue,
城市ROCKVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編20850
電話13015175556
網址https://www.maxcyte.com/
公司代碼MXCT
上市日期Mar 29, 2016
CEOMasoud (Maher)

MaxCyte Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
39.89K
+86.70%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Patrick J. Balthrop
Mr. Patrick J. Balthrop
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
398.33K
+33.52%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
230.58K
+53.13%
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
175.00K
+75.00%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
50.00K
--

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
業務USD
名稱
營收
佔比
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%
由於公司未披露,未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Product sales
5.27M
61.94%
Licenses
2.93M
34.42%
other
310.00K
3.64%

股東統計

更新時間: 12月1日 週一
更新時間: 12月1日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
其他
66.67%
持股股東
持股股東
佔比
Cadian Capital Management LP
7.71%
Mirabella Financial Services LLP
7.69%
BlackRock Institutional Trust Company, N.A.
7.54%
The Vanguard Group, Inc.
5.24%
River Global Investors LLP
5.15%
其他
66.67%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
24.33%
Investment Advisor
22.61%
Hedge Fund
17.87%
Research Firm
4.86%
Private Equity
4.73%
Individual Investor
1.74%
Venture Capital
0.36%
Bank and Trust
0.19%
Pension Fund
0.15%
其他
23.16%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
287
82.96M
77.85%
-17.02M
2025Q2
296
78.80M
73.92%
-18.62M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Cadian Capital Management LP
8.91M
8.36%
-1.11M
-11.10%
Jun 30, 2025
Mirabella Financial Services LLP
6.60M
6.19%
+2.90M
+78.38%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.21M
7.7%
+793.69K
+10.70%
Jun 30, 2025
The Vanguard Group, Inc.
5.60M
5.25%
+36.02K
+0.65%
Jun 30, 2025
River Global Investors LLP
3.25M
3.05%
+1.19M
+57.73%
Dec 31, 2024
Vitruvian Partners LLP
5.04M
4.73%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
4.23M
3.97%
+795.36K
+23.12%
Jun 30, 2025
Mudita Advisors LLP
3.37M
3.16%
+42.25K
+1.27%
Jun 30, 2025
AXA Investment Managers UK Ltd.
2.20M
2.07%
+1.22M
+123.16%
Jun 30, 2025
AXA Investment Managers Paris
2.20M
2.07%
--
--
Jul 31, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.6%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.6%
iShares Micro-Cap ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
iShares Biotechnology ETF
佔比0.01%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

MaxCyte Inc的前五大股東是誰?

MaxCyte Inc的前五大股東如下:
Cadian Capital Management LP
持有股份:8.91M
佔總股份比例:8.36%。
Mirabella Financial Services LLP
持有股份:6.60M
佔總股份比例:6.19%。
BlackRock Institutional Trust Company, N.A.
持有股份:8.21M
佔總股份比例:7.70%。
The Vanguard Group, Inc.
持有股份:5.60M
佔總股份比例:5.25%。
River Global Investors LLP
持有股份:3.25M
佔總股份比例:3.05%。

MaxCyte Inc的前三大股東類型是什麼?

MaxCyte Inc 的前三大股東類型分別是:
Cadian Capital Management LP
Mirabella Financial Services LLP
BlackRock Institutional Trust Company, N.A.

有多少機構持有MaxCyte Inc(MXCT)的股份?

截至2025Q3,共有287家機構持有MaxCyte Inc的股份,合計持有的股份價值約為82.96M,占公司總股份的77.85% 。與2025Q2相比,機構持股有所增加,增幅為3.93%。

哪個業務部門對MaxCyte Inc的收入貢獻最大?

在FY2025Q2,Product sales業務部門對MaxCyte Inc的收入貢獻最大,創收5.27M,占總收入的61.94% 。
KeyAI